Otos’ Post

I'm excited to share an inspiring case study from Nimbus Therapeutics, showcasing the incredible work of Alex Benzell and Rebecca Carazza. They developed a series of Spotfire dashboards to manage their CRO projects, achieving remarkable results: 🔹 Reduced CRO data upload time 🔹 Minimized manual intervention 🔹 Streamlined projects Their innovative approach has significantly accelerated innovation. Kudos to Alex and Rebecca for their outstanding innovation! https://bit.ly/4a4SFYG #Revvity Signals

We are excited to share our recent business update and highlight two key achievements: 🔹 Current Cash Balance: Allarity Therapeutics is thrilled to report a robust cash balance of $20 million, providing a runway extending into 2026 at our current burn rate. This financial stability enables us to continue our critical work without interruption. 🔹 Pausing the ATM: To safeguard our financial health and minimize shareholder dilution, we are pausing our At-The-Market (ATM) offering program for the foreseeable future. Our new management has made significant strides in enhancing our financial position and streamlining operations. We've also concentrated all our efforts on advancing stenoparib, our promising dual PARP and Tankyrase inhibitor, which continues to show promising results in Phase 2 trials. Click below to read the full press release ⬇️ #AllarityTherapeutics #BusinessUpdate #FinancialProgress #CancerResearch #Stenoparib

If you're looking to learn valuable tips for presenting science effectively, be sure to register for the webinar below ⤵

Various Tetracyclines (Tetracycline, Doxycycline, Minocycline, Tigecycline, Eravacycline and Omadacycline) and their spectrum of activity

Freeline and Swan to Spur new AAV Development... I couldn't resist. Syncona announced they are combining Freeline and Swan Bio to create Spur Therapeutics to advance the most viable components of the latter two companies' pipelines. That pipeline will be headlined by Freeline's Gaucher program (on the cusp of starting Ph3), and Swan's candidate in adrenomyeloneuropathy. Syncona previously took Freeline private to create new optionality for the company. This was after AAV headwinds had battered the stock and other candidates reached approval first in their prior lead therapies (hemophilia). This shows there's still interest in AAV and its proven delivery capability to diverse tissues and cells. But there is continuing culling in the industry's pipeline. Want to take a look at that pipeline? or think about how it impacts your own prioritization? Reach out and we can discuss! #venturecapital #genetherapy #pharma https://lnkd.in/g8-ZKp4C

Looking forward to our panel “The Rise of Digital Therapeutics in Clinical Care” today MedTech World with Gina Itzikowitz Florian K. Daniel Young Laura Parker Sharing an article related to our discussion today: “Digital therapeutics from bench to bedside” #medtech24

Doxy and tige and erava – oh my!  How do you differentiate their spectra of activity?  🤨 With this handy infographic!  Developed by SIDP members and sponsored by Innoviva Specialty Therapeutics

Aviceda Therapeutics has secured a $207.5 million Series C financing to support its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104 in geographic atrophy (GA). According to a press release from the company1, the Series C round was co-led by healthcare funds, Omega Funds and TCGX, with participation from multiple other investment firms Read More: https://ow.ly/P76E50UCvCY

In a recent CRA webinar on evolving business models for DTx (Digital Therapeutics) Rhett Johnson and Andy Parece discussed with a panel of industry leaders, Richard DeNunzio, Omar Manejwala, M.D., and Brion Raymond, how events in the past year, from introduction of new HSPCS billing codes to Pear Therapeutics’ bankruptcy and the transition of some DTx manufacturers to alternative business models, impact their companies. Each panelist discussed business models their company is employing, including prescription digital therapeutics, collaboration with employers to fund solutions and with pharma companies to collaborate partner in research and commercialization. The discussion covered the drivers behind the choice of each business model as well as their advantages, and showed how they are related to the specific product, indication and available clinical evidence base. To learn more and watch the webinar recording, click here: https://lnkd.in/gjdbCBTd #DigitalTherapeutics

NEW: Chroma Medicine and Nvelop Therapeutics have merged, combining into nChroma Bio. The deal is the latest signal of a volatile genetic medicines field that has leaned into consolidation to survive. ReNAgade Therapeutics and Orna Therapeutics merged together earlier this year, while other startups have flamed out like Tome Biosciences and Resonance Medicine, Inc. My latest for Endpoints News on nChroma — including how the deal started over two startups CEOs getting tacos: